Additionally, there has been no analysis of AML patient data regarding the prevalence of FLT3 mutations, clinical characteristics, other co-occurring chromosomal abnormalities, treatment regimens, or detailed survival rates. This evidence concerns the gene FLT3 and acute myeloid leukemia.